IKT - Inhibikase Therapeutics, Inc.

2
-0.100   -5.000%

Share volume: 109,431
Last Updated: 05-09-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$2.10
-0.10
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 43%
Dept financing 11%
Liquidity 48%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
8.11%
1 Month
0   0%
3 Months
-11.50%
6 Months
-30.80%
1 Year
47.06%
2 Year
-45.60%
Key data
Stock price
$2.00
P/E Ratio 
0.00
DAY RANGE
$1.94 - $2.09
EPS 
-$2.55
52 WEEK RANGE
$1.12 - $4.20
52 WEEK CHANGE
$47.06
MARKET CAP 
218.376 M
YIELD 
N/A
SHARES OUTSTANDING 
7.464 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.84
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$116,425
AVERAGE 30 VOLUME 
$117,804
Company detail
CEO: Milton H. Werner
Region: US
Website: inhibikase.com
Employees: 6
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD.

Recent news
loading